296 related articles for article (PubMed ID: 22440906)
21. Effects of Conversion to a Bicarbonate/Lactate-Buffered, Neutral-pH, Low-GDP PD Regimen in Prevalent PD: A 2-Year Randomized Clinical Trial.
Farhat K; Douma CE; Ferrantelli E; Ter Wee PM; Beelen RHJ; van Ittersum FJ
Perit Dial Int; 2017; 37(3):273-282. PubMed ID: 28348100
[TBL] [Abstract][Full Text] [Related]
22. Association Between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: The balANZ Trial.
Nataatmadja M; Cho Y; Pascoe EM; Darssan D; Hawley CM; Johnson DW;
Perit Dial Int; 2017; 37(4):407-413. PubMed ID: 28408714
[TBL] [Abstract][Full Text] [Related]
23. Association of biocompatible peritoneal dialysis solutions with peritonitis risk, treatment, and outcomes.
Cho Y; Badve SV; Hawley CM; McDonald SP; Brown FG; Boudville N; Bannister KM; Clayton PA; Johnson DW
Clin J Am Soc Nephrol; 2013 Sep; 8(9):1556-63. PubMed ID: 23949232
[TBL] [Abstract][Full Text] [Related]
24. Association of Incremental peritoneal dialysis with residual kidney function decline in patients on peritoneal dialysis: The balANZ trial.
Hayat A; Cho Y; Hawley CM; Htay H; Krishnasamy R; Pascoe E; Teitelbaum I; Varnfield M; Johnson DW
Perit Dial Int; 2023 Sep; 43(5):374-382. PubMed ID: 37259236
[TBL] [Abstract][Full Text] [Related]
25. What is the role of automated peritoneal dialysis and continuous flow peritoneal dialysis?
Diaz-Buxo JA
Contrib Nephrol; 2003; (140):264-71. PubMed ID: 12800368
[No Abstract] [Full Text] [Related]
26. Impact of Obesity on Modality Longevity, Residual Kidney Function, Peritonitis, and Survival Among Incident Peritoneal Dialysis Patients.
Obi Y; Streja E; Mehrotra R; Rivara MB; Rhee CM; Soohoo M; Gillen DL; Lau WL; Kovesdy CP; Kalantar-Zadeh K
Am J Kidney Dis; 2018 Jun; 71(6):802-813. PubMed ID: 29223620
[TBL] [Abstract][Full Text] [Related]
27. Effect of Icodextrin Solution on the Preservation of Residual Renal Function in Peritoneal Dialysis Patients: A Randomized Controlled Study.
Chang TI; Ryu DR; Yoo TH; Kim HJ; Kang EW; Kim H; Chang JH; Kim DK; Moon SJ; Yoon SY; Han SH;
Medicine (Baltimore); 2016 Mar; 95(13):e2991. PubMed ID: 27043667
[TBL] [Abstract][Full Text] [Related]
28. 33 Years of Peritoneal Dialysis-Associated Peritonitis: A Single-Center Study in Japan.
Nakao M; Yamamoto I; Maruyama Y; Nakashima A; Matsuo N; Tanno Y; Ohkido I; Ikeda M; Yamamoto H; Yokoyama K; Yokoo T
Ther Apher Dial; 2016 Feb; 20(1):60-5. PubMed ID: 26577015
[TBL] [Abstract][Full Text] [Related]
29. Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry.
Htay H; Cho Y; Pascoe EM; Darssan D; Nadeau-Fredette AC; Hawley C; Clayton PA; Borlace M; Badve SV; Sud K; Boudville N; McDonald SP; Johnson DW
Am J Kidney Dis; 2018 Jun; 71(6):814-821. PubMed ID: 29289475
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin d.
Rudnicki M; Kerschbaum J; Hausdorfer J; Mayer G; König P
Perit Dial Int; 2010; 30(5):541-8. PubMed ID: 20228174
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
[TBL] [Abstract][Full Text] [Related]
32. Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.
De Los Ríos T; Pérez-Martínez J; Portoles J; Lichodziejewska-Niemierko M; Rivera M; Nowicki M; Książek A; Tato AM; Bohnhorst C; Feriani M
Perit Dial Int; 2016 9-10; 36(5):569-72. PubMed ID: 27659931
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the BRAZPD II cohort and description of trends in peritoneal dialysis outcome across time periods.
de Moraes TP; Figueiredo AE; de Campos LG; Olandoski M; Barretti P; Pecoits-Filho R;
Perit Dial Int; 2014; 34(7):714-23. PubMed ID: 25185014
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function.
Fan SL; Pile T; Punzalan S; Raftery MJ; Yaqoob MM
Kidney Int; 2008 Jan; 73(2):200-6. PubMed ID: 17914351
[TBL] [Abstract][Full Text] [Related]
35. Biocompatible peritoneal dialysis solution preserves residual renal function.
Kim S; Oh KH; Oh J; Kim SJ; Chung W; Song YR; Na KY; Oh YK; Ahn C; Kim SG; Tan KC
Am J Nephrol; 2012; 36(4):305-16. PubMed ID: 23007025
[TBL] [Abstract][Full Text] [Related]
36. Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.
Pletinck A; Vanholder R; Veys N; Van Biesen W
Nat Rev Nephrol; 2012 Sep; 8(9):542-50. PubMed ID: 22777203
[TBL] [Abstract][Full Text] [Related]
37. Impact of continuous quality improvement initiatives on clinical outcomes in peritoneal dialysis.
Yu Y; Zhou Y; Wang H; Zhou T; Li Q; Li T; Wu Y; Liu Z
Perit Dial Int; 2014 Jun; 34 Suppl 2(Suppl 2):S43-8. PubMed ID: 24962962
[TBL] [Abstract][Full Text] [Related]
38. Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.
Yohanna S; Alkatheeri AM; Brimble SK; McCormick B; Iansavitchous A; Blake PG; Jain AK
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1380-8. PubMed ID: 26048890
[TBL] [Abstract][Full Text] [Related]
39. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: the NEXT-PD study.
Nakayama M; Miyazaki M; Honda K; Kasai K; Tomo T; Nakamoto H; Kawanishi H
Perit Dial Int; 2014; 34(7):766-74. PubMed ID: 24497585
[TBL] [Abstract][Full Text] [Related]
40. Comparing long-term outcomes between early and delayed initiation of peritoneal dialysis following catheter implantation.
Pai MF; Yang JY; Chen HY; Hsu SP; Chiu YL; Wu HY; Tsai WC; Peng YS
Ren Fail; 2016 Jul; 38(6):875-81. PubMed ID: 27056580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
